Could the conservative approach be considered safe in the treatment of locally advanced rectal cancer in case of a clinical near-complete or complete response? A retrospective analysis

Eh, 2014, Time for a renewed strategy in the management of rectal cancer: critical reflection on the surgical management of rectal cancer over 100 years, Dis Colon Rectum, 57, 399, 10.1097/DCR.0000000000000043 Bahadoer, 2021, Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial, Lancet Oncol, 22, 29, 10.1016/S1470-2045(20)30555-6 Glynne-Jones, 2018, Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 29, 10.1093/annonc/mdy161 Ngan, 2012, Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04, J Clin Oncol, 30, 3827, 10.1200/JCO.2012.42.9597 Bujko, 2016, Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study, Ann Oncol, 27, 834, 10.1093/annonc/mdw062 Maas, 2010, Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data, Lancet Oncol, 11, 835, 10.1016/S1470-2045(10)70172-8 Capirci, 2008, Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR Patients, Int J Radiat Oncol Biol Phys, 72, 99, 10.1016/j.ijrobp.2007.12.019 Gambacorta, 2021, Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials, Radiother Oncol, 154, 154, 10.1016/j.radonc.2020.09.026 Borschitz, 2008, Neoadjuvant chemoradiation and local excision for T2–3 rectal cancer, Ann Surg Oncol, 15, 712, 10.1245/s10434-007-9732-x Lai, 2016, 1, Jao S-W C-WH 3. Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or “watch and wait”, Int J Color Dis, 31, 413, 10.1007/s00384-015-2460-y Guren, 2005, Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer, Eur J Surg Oncol, 31, 735, 10.1016/j.ejso.2005.05.004 Fleming FJ, Monson JRT The contemporary (over)treatment of rectal cancer: the goldilocks effect. Dis Colon Rectum 2014; 57:403–6. https://doi.org/10.1097/DCR.0000000000000042. Smith, 2015, Advances and challenges in treatment of locally advanced rectal cancer, J Clin Oncol, 33, 1797, 10.1200/JCO.2014.60.1054 Beets, 2015, A new paradigm for rectal cancer: Organ preservation Introducing the International Watch & Wait Database (IWWD), Eur J Surg Oncol, 41, 1562, 10.1016/j.ejso.2015.09.008 Habr-Gama A, Perez RO, NadalinW, sabbagaJ, Ribeiro JrU, Silva AH et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long- term results. Ann Surg 2004;240:711–7. https://doi.org/10.1097/01.sla.0000141194.27992.32. Habr-Gama, 2014, Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control, Int J Radiat Oncol Biol Phys, 88, 822, 10.1016/j.ijrobp.2013.12.012 Martin, 2012, Winter DC Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer, Br J Surg, 99, 918, 10.1002/bjs.8702 Maas, 2011, Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer, J Clin Oncol Off J Am Soc Clin Oncol, 29, 4633, 10.1200/JCO.2011.37.7176 Dalton RSJ, Velineni R, Osborne ME,Thomas R, Harries S, Gee A S,IRD. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? Color Dis 2012; 14:567–71. https://doi.org/10.1111/j.1463-1318.2011.02752.x. Hughes, 2010, Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy?, Acta Oncol (Madr), 49, 378, 10.3109/02841860903483692 Simpson, 2020, Long-term outcomes of real world “watch and wait” data for rectal cancer after neoadjuvant chemoradiotherapy, Color Dis, 22, 1568, 10.1111/codi.15177 van der Valk MJM, E Hilling D, Bastiaannet E, Kranenbarg E M-K, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet (London, England) 2018;391:2537–45. https://doi.org/10.1016/S0140-6736(18)31078-X. Smith, 2019, Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA, Oncol, 5, e185896 Valentini, 2019, The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)–cT3 rectal cancer, Radiother Oncol, 134, 110, 10.1016/j.radonc.2018.11.023 Lupattelli, 2017, Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: Short-term results of a multicentric study, Radiat Oncol, 12, 10.1186/s13014-017-0870-4 Rödel, 2015, Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial, Lancet Oncol, 16, 979, 10.1016/S1470-2045(15)00159-X Gérard, 2015, Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial, Radiother Oncol, 115, 246, 10.1016/j.radonc.2015.04.003 Maas, 2015, Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment, Ann Surg Oncol., 22, 3873, 10.1245/s10434-015-4687-9 Beets-Tan, 2018, Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting, Eur Radiol, 28, 1465, 10.1007/s00330-017-5026-2 Macchia, 2017, Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients, Clin Transl Radiat Oncol, 4, 8, 10.1016/j.ctro.2017.04.004 Simillis, 2020, Postoperative chemotherapy improves survival in patients with resected high-risk Stage II colorectal cancer: results of a systematic review and meta-analysis, Color Dis, 22, 1231, 10.1111/codi.14994 Arraras, 2013, Quality of life assessment by applying EORTC questionnaires to rectal cancer patients after surgery and neoadjuvant and adjuvant treatment, Rev Esp Enferm Dig, 105, 255, 10.4321/S1130-01082013000500003 Pascual-Russo, 2020, Better quality of life and reduced fecal incontinence in rectal cancer patients with the watch-and-wait follow-up strategy, Rev Gastroenterol Mex Smith JD, Ruby JA, Goodman KA, Saltz LB,Guillem JG,Weiser MR, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg 2012;256:965–72. Doi: 10.1097/SLA.0b013e3182759f1c. Rullier, 2020, Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial, Lancet Gastroenterol Hepatol, 5, 465, 10.1016/S2468-1253(19)30410-8 Bach, 2021, Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study, Lancet Gastroenterol Hepatol, 6, 92, 10.1016/S2468-1253(20)30333-2 Dossa, 2017, A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol, 2, 501, 10.1016/S2468-1253(17)30074-2 Renehan, 2016, Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis, Lancet Oncol, 17, 174, 10.1016/S1470-2045(15)00467-2 Dattani M, Heald RJ, Goussous G, Broadhurst J, São Julião GP, Habr-Gama A, Perez RO. Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis. Ann Surg 2018;268:955–67. Doi: 10.1097/SLA.0000000000002761 B J P Hupkens1,MH Martens,JH Stoot,M Berbee,J Melenhorst,R G Beets-Tan et al Quality of Life in Rectal Cancer Patients After Chemoradiation: Watch-and-Wait Policy Versus Standard Resection A Matched - Controlled Study Dis Colon Rectum 2017; 60(10): 1032-1040 doi: 10.1097/DCR.0000000000000862. BB Vailati,A Habr-Gama,AE Mattacheo,GP Julião,RO Perez Quality of Life in Patients With Rectal Cancer After Chemoradiation: Watch-and-Wait Policy Versus Standard Resection-Are We Comparing Apples to Oranges? Dis Colon Rectum 2018 Mar;61(3):e21. doi: 10.1097/DCR.0000000000001018. Badic, 2018, Long-term functional and oncological results after sphincter-saving resection for rectal cancer - Cohort study, Int J Surg, 52, 1, 10.1016/j.ijsu.2018.02.003 Smith F Mc, Rao C, Perez RO, Bujko K, Athanasiou T, Habr-Gama A. Avoiding radical surgery improves early survival in elderly patients with rectal cancer, demonstrating complete clinical response after neoadjuvant therapy: results of a decision-analytic model. Dis Colon Rectum 2015;58:159–71. https://doi.org/10.1097/DCR.0000000000000281.